Indeed, careful studies support that a PSA screening every two years reduces the death rate for PCa of about 80% compared with annual screening while decreasing both the number of tests and the chance of a false-positive test by 50% and overdiagnosis by 30%. Here, KLK3 is linked to posterior cortical atrophy.